Unravelling the benefits of nutraceutical seaweed <i>Ecklonia</i> to reaping its pharmaceutical approaches

Growing concern for human health has driven researchers worldwide to reap the benefits of marine algal species due to their potent, multifaceted nature and bioactivity. These are nutritionally dense sources of bioactive compounds with distinct properties. The seawater ecosystem is a treasury of secondary bioactive compounds with higher therapeutic potential and diverse uniqueness, like phlorotannin and halo compounds. Several studies have highlighted the bioactive molecules obtained from one of the brown algae, <i>Ecklonia</i>, which can reduce the activities of key regulators like TNF-a, NF-kB, MAPKs. Hence, a step forward in our current study, we comprehend the function of <i>Ecklonia</i> compounds in disease models, including Alzheimer’s, coronary artery disease and Type 2 Diabetes, by utilizing the Network Pharmacology approach. This method integrates bioinformatics, systems biology, and pharmacology to understand the complex interactions between bioactive compounds and biological systems. Our studies highlighted the possible interactions of the compound with significant genes like HMGCR, PTGS2, ADRB2, AURKA, and PDE4D, which were identified as potential targets of therapeutic importance to drug development and design drug by the pharmaceutical industries.